Microbix Biosystems Inc. (
TSX: MBX, OTCQX: MBXBF,
Microbix®), a life sciences innovator, manufacturer, and
exporter, announces that it is presenting results of its Quality
Assessment Products (“
QAPs™”) for supporting the
clinical use and accuracy of multiplex tests for four of the most
prevalent sexually-transmitted infections (“
STIs”)
at the American Association of Clinical Chemistry
(“
AACC”) conference taking place in Anaheim,
California July 23 to 27, 2023.
At AACC, Microbix will exhibit alongside leading
firms that provide tests to diagnose and direct treatment of STIs
and other infectious diseases. Microbix will thereby showcase its
ever-growing portfolio of QAPs that help ensure the accuracy of
antigen and molecular (i.e., “PCR”) tests and
their workflows.
Also at AACC, Microbix will present a poster
titled “Evaluating the Performance of Emerging STI Point of Care
Assays Using Novel, Room Temperature Stable CT/NG/TV/MG Positive
Swab Quality Control Materials.” The poster reviews the performance
of novel PROCEED®FLOQ® (RUO) QAPs to support the clinical use and
accuracy of multiplex PCR tests for Chlamydia trachomatis (CT),
Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and
Mycoplasma genitalium (MG) – four of the most prevalent STIs. The
poster can be read at https://microbix.com and a REDx®FLOQ®
(IVD) product format is also available.
Point of Care Tests (“PoCTs”)
that can distinguish between STI-causing pathogens promise improved
access to care and faster turnaround time from patient-sampling to
test-result. However, users of such PoCTs must have accurate and
robust test-control materials for quality management purposes.
Microbix therefore developed a whole-workflow multiplex STI QAP
desiccated on a Copan FLOQSwab® that is stable at 2-30°C and
contains inactive whole-genome target pathogens. The poster
evaluated its performance with multiple diagnostic platforms in
current use and in development, namely the Abbott Alinity™ m
STI assay, Aprimeo/Bosch Vivalytic™ STI Assay, BD
MAX™ CT/GC/TV assay, Cepheid Xpert® CT/NG and TV
assays, Seegene Novaplex™ CT/NG/TV/MG assay, an
IVD assay in late-stage development, and a lab-developed assay.
Dr. Amer Alagic, an author of the poster and
Director of R&D at Microbix, commented prior to his
presentation of the poster at AACC “Microbix’s whole-genome and
room-temperature stable FLOQSwab-formatted QAPs continue to
demonstrate their ability to support quality management on a wide
range of molecular assays and instrument platforms. We’re pleased
to be offering Microbix QAPs to support clinically-important STI
testing – as tools for validation, verification, and training, as
external quality assessment samples, and as in-kit controls.”
Purchase enquires for these and all Microbix
QAPs can be e-mailed to customer.service@microbix.com.
About Microbix Biosystems
Inc.Microbix Biosystems Inc. creates proprietary
biological products for human health, with over 100 skilled
employees and annualized sales targeting C$ 2.0 million per month.
It makes a wide range of critical ingredients and devices for the
global diagnostics industry, notably antigens for immunoassays and
its laboratory quality assessment products (QAPs™) that support
clinical lab proficiency testing, enable assay development and
validation, or help ensure the quality of clinical diagnostic
workflows. Its antigens drive the antibody tests of approximately
100 diagnostics makers, while QAPs are sold to clinical lab
accreditation organizations, diagnostics companies, and clinical
labs. Microbix QAPs are now available in over 30 countries,
supported by a network of 10 international distributors. Microbix
is ISO 9001 & 13485 accredited, U.S. FDA registered, Australian
TGA registered, Health Canada establishment licensed, and provides
CE marked products.
Microbix also applies its biological expertise
and infrastructure to develop other proprietary products and
technologies, most notably viral transport medium (DxTM™) to
stabilize patient samples for lab-based molecular diagnostic
testing and Kinlytic® urokinase, a biologic thrombolytic drug used
to treat blood clots. Microbix is traded on the TSX and OTCQX, and
headquartered in Mississauga, Ontario, Canada.
Forward-Looking InformationThis
news release includes “forward-looking information,” as such term
is defined in applicable securities laws. Forward-looking
information includes, without limitation, discussion of AACC, the
Poster, the STI QAPs, or their relevance, Microbix’s or others’
products or services, business and business results, goals or
outlook, risks associated with financial results and stability,
development projects such as those referenced in its presentations,
regulatory compliance and approvals, sales to foreign
jurisdictions, engineering and construction, production (including
control over costs, quality, quantity or timeliness of delivery),
currency exchange rates, maintaining adequate working capital or
raising new capital on acceptable terms or at all, and other
similar statements about anticipated future events, conditions or
results that are not historical facts. These statements reflect
management’s current estimates, beliefs, intentions, and
expectations; they are not guarantees of future performance.
Microbix cautions that all forward-looking information is
inherently uncertain and actual performance may be affected by a
number of material factors, many of which are beyond its control.
Accordingly, actual future events, conditions and results may
differ materially from the estimates, beliefs, intentions, and
expectations expressed or implied in the forward-looking
information. All statements are made as of the date of this news
release and represent Microbix’s judgement as of the date of this
new release, and it is under no obligation to update or alter any
forward-looking information.
Please visit https://microbix.com or www.sedar.com
for recent Microbix news and filings.
For further information, please contact Microbix
at:
Cameron Groome, CEO(905) 361-8910 |
Jim Currie, CFO(905) 361-8910 |
Deborah Honig, Investor RelationsAdelaide Capital Markets(647)
203-8793 ir@microbix.com |
Copyright © 2023 Microbix Biosystems Inc.
Microbix®, DxTM™, Kinlytic®, PROCEEDx®, QAPs™, and REDx® are
trademarks of Microbix Biosystems Inc.PROCEEDx®FLOQ® and REDx®FLOQ®
are trademarks of Microbix Biosystems Inc. in collaboration with
Copan Italia S.p.A.Copan®, FLOQ®, and FLOQSwab® are trademarks of
Copan Italia S.p.A.Other companies’ names and products are
protected by their respective trademarks.
Microbix Biosystems (TSX:MBX)
Historical Stock Chart
From Apr 2024 to May 2024
Microbix Biosystems (TSX:MBX)
Historical Stock Chart
From May 2023 to May 2024